SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 137 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,279,890 | +162.9% | 914,593 | +278.9% | 0.00% | +200.0% |
| Q2 2023 | $5,051,455 | -85.0% | 241,350 | -84.9% | 0.00% | -85.7% |
| Q1 2023 | $33,763,889 | -21.6% | 1,598,669 | -5.6% | 0.01% | -30.0% |
| Q4 2022 | $43,088,199 | +22.9% | 1,693,053 | +16.1% | 0.01% | +25.0% |
| Q3 2022 | $35,052,000 | -0.2% | 1,458,671 | -20.1% | 0.01% | -11.1% |
| Q2 2022 | $35,139,000 | +7.6% | 1,826,352 | -2.8% | 0.01% | +28.6% |
| Q1 2022 | $32,649,000 | -26.5% | 1,878,540 | -7.5% | 0.01% | -22.2% |
| Q4 2021 | $44,444,000 | +25.0% | 2,030,327 | +9.1% | 0.01% | +28.6% |
| Q3 2021 | $35,557,000 | +1.7% | 1,860,657 | -8.7% | 0.01% | -12.5% |
| Q2 2021 | $34,975,000 | -32.3% | 2,036,931 | -11.8% | 0.01% | -33.3% |
| Q1 2021 | $51,637,000 | +6.0% | 2,309,323 | +5.4% | 0.01% | 0.0% |
| Q4 2020 | $48,732,000 | +445.7% | 2,191,218 | +262.2% | 0.01% | +500.0% |
| Q3 2020 | $8,930,000 | -45.5% | 605,014 | -45.3% | 0.00% | -66.7% |
| Q2 2020 | $16,399,000 | +3731.5% | 1,106,580 | +2734.1% | 0.01% | – |
| Q1 2020 | $428,000 | -8.2% | 39,045 | -26.5% | 0.00% | – |
| Q4 2019 | $466,000 | -34.7% | 53,098 | -44.4% | 0.00% | – |
| Q3 2019 | $714,000 | +490.1% | 95,500 | +634.6% | 0.00% | – |
| Q2 2019 | $121,000 | +12.0% | 13,000 | -36.6% | 0.00% | – |
| Q1 2019 | $108,000 | -78.4% | 20,500 | -81.8% | 0.00% | – |
| Q4 2018 | $501,000 | -20.2% | 112,607 | +44.8% | 0.00% | – |
| Q3 2018 | $628,000 | +79.4% | 77,755 | +56.1% | 0.00% | – |
| Q2 2018 | $350,000 | – | 49,798 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |